NCT00320307已完成1 期
An Open-Label, Two-Period, Crossover, Pharmacokinetic Study of Abacavir and Its Intracellular Anabolite Carbovir Triphosphate Following Once-Daily and Twice-Daily Administration of Abacavir in HIV-Infected Subjects.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- To assess the pharmacokinetics of intracellular CBV-TP at steady state following administration of 600 mg QD and 300 mg BID ABC-containing regimens in HIV infected adult subjects.
研究概览
简要总结
The purpose of the study is to look at the levels of the drug abacavir (ABC) in blood. Also, the study will look at the levels of carbovir triphosphate (CBV-TP), which is the active substance produced from ABC in the bodyâ s cells which helps prevent HIV from multiplying. CBV-TP will be measured in specific blood cells. The amount of ABC and CBV-TP will be looked at when subjects receive ABC as a 300mg dose twice a day and compared with the levels when they receive ABC as a 600mg dose once a day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults , inclusively.
- •Documented HIV-1 infection (documented by historical data or current validated assay).
- •Undetectable viral load.
- •Currently on an ABC-tablet containing regimen for at least 8 weeks.
- •Willingness to temporarily switch ABC schedule from BID to QD, or vice versa, for 11 days.
- •Weigh between 40-100kg, inclusive.
排除标准
- •Subjects who are receiving tenofovir.
- •Previous study participation in other experimental drug trial(s) within 30 days before the screening phase of the study.
- •Subjects who currently regularly take drugs-of-abuse, with the exception of cannabinoids.
- •Subjects who cannot refrain from taking herbal remedies during the course of the study.
- •Subjects who regularly consume more than an average amount of alcohol per day.
- •Poor general health preventing fasting or blood sampling.
- •Subjects who are not able to discontinue use of hydroxyurea, mycophenolate or ribavirin for 14 days prior to entering the study until discharge from the study.
- •An unwillingness of a male subject to abstain from sexual intercourse with women of childbearing potential or an unwillingness to use a condom in addition to having their female partner use another form of contraception.
- •The subject is pregnant or nursing an infant.
- •History of symptoms consistent with a hypersensitivity reaction to ABC.
- •Positive HCV Antibody or HepBsAg (Hepatitis B surface antigen).
结局指标
主要结局
To assess the pharmacokinetics of intracellular CBV-TP at steady state following administration of 600 mg QD and 300 mg BID ABC-containing regimens in HIV infected adult subjects.
时间窗: throughout the study
次要结局
- - To compare plasma concentrations of ABC, and intracellular CBV-TP - To assess the safety and tolerability of dosing with ABC 300mg BID and 600mg QD. - To assess potential gender effects in the pharmacokinetics of ABC.(throughout the study)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)HIV InfectionNCT01900106University of Modena and Reggio Emilia47
已完成
1 期
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of AgeHIV InfectionsNCT03760458National Institute of Allergy and Infectious Diseases (NIAID)57
已完成
1 期
Blood Levels of Abacavir After One Dose in HIV-Infected Children and AdolescentsHIV InfectionsNCT00011479National Institute of Allergy and Infectious Diseases (NIAID)24
已完成
2 期
Abacavir and Lamivudine PK in ChildrenHIVNCT01656122The HIV Netherlands Australia Thailand Research Collaboration30
终止
2 期
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus InfectionChronic Hepatitis BNCT04781647Assembly Biosciences54